Navigation Links
Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting

reater than 10 month survival criteria.

Definitive Phase III data regarding the use of ERBITUX in 1st line NSCLC are expected to be available later this year from two large randomized trials (FLEX and BMS-099) that have enrolled approximately 1800 patients.

Pancreatic Cancer

In pancreatic cancer, a notoriously difficult-to-treat cancer, the Phase III SWOG S0205 trial did not meet its primary end point. On-going trials are continuing to investigate additional combinations of ERBITUX with chemotherapy and biologics in patients with this aggressive cancer for whom treatment options remain acutely limited.

Other ERBITUX data presented at ASCO included the following:

-- Two randomized studies evaluated ERBITUX combined with oxaliplatin-based chemotherapy in first line mCRC. OPUS, a randomized Phase II study, demonstrated approximately a 10% improvement in response rate (45.6% vs 35.7%) compared to chemotherapy alone. This difference, however, was not statistically significant. However, for a subgroup of patients with an ECOG performance status of 0 and 1 the response rate was statistically in favor of the ERBITUX/FOLFOX combination. COIN, a randomized Phase III study, showed that ERBITUX can be safely combined with three different oxaliplatin regimens.

-- The feasibility of ERBITUX administration at 500 mg/m2 every 2 weeks as 60 minute infusion was reported in mCRC patients with refractory disease. This data corroborates previous findings suggesting that ERBITUX may be administered every two weeks.

-- In vitro data confirmed that ERBITUX, an IgGI monoclonal antibody, induces antibody-dependent cellular cytotoxicity (ADCC) in contrast to the lack of such activity in IgG2 monoclonal antibodies.

-- Erbitux plus radiation is currently a standard of care for patients with locally advanced Head and Neck cancer. The Eastern Cooperative Oncology Group reported promising results of a Phase II neoadjuvant study evaluating ind
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
2. Genetic Analysis Systems Enter the Clinical Mainstream
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
5. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Extensive Clinical Data Erbitux Presented the ASCO Annual Meeting
(Date:6/2/2015)... ANGELES , June 2, 2015  CytRx Corporation ... company specializing in oncology, today announced that it has ... pending in the Delaware Court ... the Company,s current and former directors and officers, and ... The lawsuit, captioned In re CytRx Corp. Stockholder ...
(Date:6/2/2015)... DUBLIN , June 02, 2015 ... the addition of the "Electrophysiology Market by ... (Cryoablation, RF, Microwave), Lab Devices (Mapping, Recording, Generator, ... Global Forecasts to 2019" report to their ... is estimated to grow at a significant CAGR ...
(Date:6/2/2015)... , Minn. and WELLESLEY, Mass., June 2, 2015 /PRNewswire/ ... principal owner, Ampersand Capital Partners (Ampersand), announced the ... operation of Array BioPharma Inc. (Array).  Accuratus was ... Eagan, MN acquired Microtest ... GLP analytical and microbial testing services to the ...
Breaking Medicine Technology:CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 2CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 3CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware 4Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 2Global Electrophysiology Market Report 2015-2019 - Product, Ablation Catheter, Lab Devices & Indication Analysis 3Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma 2Accuratus Lab Services Expands Capabilities with Acquisition of CMC Operation of Array BioPharma 3
... July 7, 2010 Elsevier is,pleased to announce the appointment of prominent new ... , , ... , , , ... is clinical research lead at the Department of,Endocrinology, Diabetes and Metabolism at Beth Israel ...
... , July 6 US WorldMeds is ... for injection), the first patented scientific advancement in the ... dantrolene sodium for injection has been dramatically reduced to ...  Revonto™ retains the cost-savings of the original dantrolene sodium ...
Cached Medicine Technology:Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors 2Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors 3Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors 4Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors 5Elsevier Appoints Top Diabetes and Endocrinology Researchers as Editors 6US WorldMeds Announces the Launch of Revonto™ (dantrolene sodium for injection) 2
(Date:6/2/2015)... June 02, 2015 With a dedicated focus ... & Health Care has hired Leslie Young as director ... human resource initiatives to better understand and respond to the ... Tutera’s 47 communities in 13 states across the country. , ... of personalized support to our residents, we are making it ...
(Date:6/2/2015)... June 02, 2015 DiaTech Oncology, ... response profiling test to help oncologists provide personalized ... of American Pathologists (CAP) for its laboratories in ... certification is equivalent to the ‘Good Housekeeping’ seal ... chief executive officer for DiaTech. “It’s a rigorous ...
(Date:6/2/2015)... Though almost the entire Park family was born with HHT, ... lives. Organizing and hosting the June 14 event is just ... fullest and spreading awareness of HHT. , “I've been scanned ... my life in a bubble because something bad might happen,” ... look back on your life with regret because you let ...
(Date:6/2/2015)... 02, 2015 For those that have ... exposed to harmful germs, chemicals and bodily fluids from ... to an inventor from Queens Village, N.Y., their worries ... an efficient, fun, hygienic way to store and dispense ... to bugs, chemicals and germs. Furthermore, it insures that ...
(Date:6/2/2015)... June 02, 2015 The health care ... a pioneering provider of value-based care will now offer ... Orange and Sullivan Counties. The newly launched Crystal Run ... its commercial Small Group Preferred Provider Organization (PPO) and ... Run Healthcare’s Managing Partner and CEO, Hal Teitelbaum, ...
Breaking Medicine News(10 mins):Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 2Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 3Health News:Tutera Senior Living & Health Care Hires HR Pro Leslie Young to Lead New Initiatives to Become Employer of Choice 4Health News:DiaTech Oncology Gains College of American Pathologists Accreditation for U.S. CorrectChemo Laboratory 2Health News:Family brings awareness to genetic disease at first Memphis walk 2Health News:Dental Storage and Dispensing Unit Invented by InventHelp Client (LGI-1890) 2Health News:Leading Health Care Innovator Poised to Deliver New Health Coverage Options To The Hudson Valley Region 2Health News:Leading Health Care Innovator Poised to Deliver New Health Coverage Options To The Hudson Valley Region 3
... N.V., a global specialty pharmaceutical company, announced today that ... reached a significant milestone in the development of ... ,GSK has started a registration bioequivalence study ... payment of $1 million to Eurand in recognition of ...
... Robots that perform surgery can be driven by surgeons who ... from a computer console . The International Journal of Medical ... surgeons and scientists have shown that the surgeon and robot ... ,Robots are starting to prove that they can be used ...
... Council for Responsible Nutrition (CRN) today responded to a ... prevention of cancer in the June 6 issue of ... by urging the scientific research community, the media, and ... undo the important strides made in recent years in ...
... June 5 /PRNewswire/ -- After receiving requests from models, ... professional version of DermaLastyl, DermaPlus, Inc. recently launched ... E versions of DermaLastyl currently available, the Bx Pro/Face ... times the amount of elastin being lost in one ...
... Wednesday a major recall of its anti-HIV drug Viracept after ... ,recalls in Europe and some other world regions ... in a statement. ,It said that the United ... ,"Roche has received several reports that some batches ...
... fate of one of France's best-loved cheeses is in question ... traditional variety made with untreated "raw" milk -- stopped ... the fury of purists, Lactalis and the Isigny Cooperative -- ... Camembert made in the northwest region of Normandy -- have ...
Cached Medicine News:Health News:Robotic Surgery A Cutting Edge in Medical Field 2Health News:CRN Emphasizes Importance of Folic Acid Benefits 2Health News:Fate of France's Cheeses in Doubt as Producers Cite Health Risks 2Health News:Fate of France's Cheeses in Doubt as Producers Cite Health Risks 3
... a monoclonal antibody based colorimetric test ... Neisseria gonorrhoeae. The test requires less ... no heating or pretreatment. The test ... fresh cultures. GonoGen&trade II eliminates agglutination, ...
Culture Confirmation Tests...
... GC is a novel device for ... Neisseria gonorrhoeae and Neisseria meningitidis. ... life and is easily transportable as ... inoculate, incubate and examine the growth ...
... (Nidek Advanced Vision Information System) is an ... software on a platform designed to communicate ... The network can be expanded in various ... to Nidek products but also to fundus ...
Medicine Products: